BioMarin Appoints Arpit Davé As Executive Vice President And Chief Digital And Information Officer; Strengthens Digital And AI Strategy

BioMarin Pharmaceutical has appointed Arpit Davé as Executive Vice President and Chief Digital and Information Officer, a newly created role that reports directly to President and CEO Alexander Hardy. In this position, Davé will lead BioMarin’s enterprise technology, data science, and digital transformation strategy to help drive value for patients, employees, and shareholders.

Davé brings more than two decades of experience in information technology and artificial intelligence within the biopharmaceutical sector. He joins BioMarin from Amgen, where he spent over seven years in senior technology leadership roles, most recently guiding teams responsible for AI-driven digital transformation and innovation aimed at keeping the company competitive in a rapidly evolving technology landscape.

"Arpit is a visionary thinker and talented leader who brings to this role a deep understanding of the biopharmaceutical industry and a track record of using technology and AI to deliver for patients and the business," said Mr. Hardy. "He will be responsible for building a strategic vision and roadmap, deploying technologies that will further differentiate and improve BioMarin's business operations across the company from research and development to our manufacturing and commercial organizations, now and in the future."

Before his time at Amgen, Davé held leadership roles at Bristol Myers Squibb and Merck, focusing on CIO leadership, data science, and research and development. He holds a master’s degree in industrial engineering from the University of Texas and a bachelor’s degree in mechanical engineering from S.P. University in India.

"I have long admired BioMarin's dedication to people living with rare diseases, and I am excited to work as part of this team to create undeniable value for patients, employees and shareholders," said Mr. Davé. "I am honored to join BioMarin at this pivotal moment where the convergence of biology, data and AI offers unprecedented potential; my focus will be on empowering our world-class teams and driving innovation to translate these capabilities into faster insights and the accelerated delivery of life-changing therapies to the patients who depend on us."

BioMarin is a global biotechnology company dedicated to developing therapies for rare genetic diseases. Founded in 1997 and headquartered in San Rafael, California, the company offers eight commercial products and a robust pipeline, aiming to deliver category-defining medicines with a meaningful impact on patients’ lives.